Impaired phagocyte respiratory burst responses to opportunistic fungal pathogens in transplant recipients: In vitro effect of r-metHuG-CSF (Filgrastim)

Transplant Infectious Disease

Volumn 5, Issue 1, 2003, Pages 29-37

  Pursell, K ^a   Verral, S ^a   Daraiesh, F ^a   Shrestha, N ^a   Skariah, A ^a   Hasan, E ^a   Pitrak, David ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Filgrastim; Fungi; Granulocyte colony stimulating factor; Phagocytes; Transplantation

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ASPERGILLUS; AUTOTRANSPLANTATION; CANDIDA; CELL FUNCTION; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYPTOCOCCUS; DRUG EFFECT; FUNGUS GROWTH; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION SENSITIVITY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MYCOSIS; OPPORTUNISTIC INFECTION; OPSONIZATION; ORGAN TRANSPLANTATION; PHAGOCYTE; PRIORITY JOURNAL; RESPIRATORY BURST; RHIZOPUS;

EID: 0037672836     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2003.00004.x     Document Type: Article

References (63)

1. United Network for Organ Sharing (UNOS); 1996 Annual Report; The US Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network. Transplant Data 1988-1995. US Department of Health and Human Services.
2. PAYA CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993: 16: 677-688.
3. PATEL R, PAYA CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997: 10: 86-124.
4. PATTERSON DL, SINGH N. Invasive aspergillosis in transplant recipients. Medicine 1999: 78: 123-138.
5. LIN S, SCHRANZ J, TEUTSCH SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001: 32: 358-366.
6. RUBIN RH. Infection in the organ transplant recipient. In: RUBIN RH, YOUNG LS, eds. Clinical Approach to Infection in the Compromised Host (3rd edn.) New York: Plenum Press, 1994: 629-705.
7. LEHRER RI, GANZ T, SELSTED ME, BABIOR BM, CURNUTTE JT, Neutrophils and host defense. Ann Intern Med 1988: 109: 127-142.
8. SAWYER DW, DONOWITZ GR, MANDELL GL. Polymorphonuclear neutrophils: an effective antimicrobial force. Rev Infect Dis 1989: 11 (Suppl. 7): S1532-S1544.
9. JOHNSTON RB JR. Current concepts: immunology, monocytes and macrophages. N Engl J Med 1988: 318: 747-752.
10. LILES WC, HUANG JE, VAN BURIK JH, BOWDEN RA, DALE DC. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis 1997: 175: 112-115.
11. LA ROCCO MT, BURGERT SJ. Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation. Clin Microbiol Rev 1997: 10: 277-297.
12. RABKIN JM, OROLOFF SL, CORLESS CL, et al. Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg 2000: 179: 426-500.
13. GROSSI P, FARINA C, FLOCCHI R, DALLA GASPERINA D. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000: 70: 112-116.
14. KRUGER W, RUSSMAN B, KROGER N, et al. Early infections in patients undergoing bone marrow or blood stem cell transplantation - a 7 year single centre investigation of 409 cases. Bone Marrow Transplant 1999: 23: 589-597.
15. FISHMAN JA, RUBIN RA. Infection in organ-transplant recipients. N Engl J Med 1998: 338: 1741-1751.
16. GADISH M, KLETTER Y, FLIDEL O, NAGLER A, SLAVIN S, FABIAN I. Effects of recombinant human granulocyte and granulocyte-macrophage colony-stimulating factors on neutrophil function following autologous bone marrow transplantation. Leuk Res 1991: 15: 1175-1182.
17. KATOH M, TAKADA M, NAKAYAMA M, SHIKOSHI K, UMEDA M, TSUJI A. Combined deficiency in neutrophil functions after bone marrow transplantation and the in vitro effect of granulocyte colony-stimulating factor. Rinsho Ketsueki 1997: 38: 566-571.
18. ZIMMERLI W, ZARTH A, GRATWOHL A, SPECK B. Neutrophil function and pyogenic infections in bone marrow transplant recipients. Blood 1991: 77: 393-399.
19. LEVITZ SM. Overview of host defenses in fungal infections. Clin Infect Dis 1992: 14: S37-S42.
20. BABIOR BM, STOSSEL TP. Phagocytes and nonneoplastic phagocyte diseases. In: BABIOR BM, STOSSEL TP, eds. Hematology. A Pathophysiologic Approach (2nd edn). New York, NY: Churchill Livingstone, 1990: 265-289.
21. LEHRER RI, CLINE MJ. Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection. J Clin Invest 1969: 48: 1478-1488.
22. DIAMOND RD, CLARK RA, HAUDENSCHILD CC. Damage to Candida albicans hyphae and pseudohyphae by the myeloperoxidase system and oxidative products of neutrophil metabolism in vitro. J Clin Invest 1980: 66: 908-917.
23. DIAMOND RD, KRZESICKI R. Mechanisms of attachment of neutrophils to Candida albicans pseudohyphae in the absence of serum, and of subsequent damage to pseudohyphae by microbicidal processes of neutrophils in vitro. J Clin Invest 1978: 61: 360-369.
24. DIAMOND RD, KRZESICKI R, JAO W. Damage to pseudohyphal forms of Candida albicans by neutrophils in the absence of serum. J Clin Invest 1978: 61: 349-359.
25. DIAMOND RD, KRZESICKI R, EPSTEIN B, JAO W. Damage to hyphal forms of fungi by human leukocytes in vitro: a possible host defense mechanism in aspergillosis and mucormycosis. Am J Pathol 1978: 91: 313-328.
26. SCHAFFNER A, DOUGLAS H, BRAUDE A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. J Clin Invest 1982: 69: 617-631.
27. REX JH, BENNETT JE, GALLIN JL, MALECH HL, MELNICK DA. Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis 1990: 162: 523-528.
28. PERFECT JR. Cryptococcosis. Infect Dis Clin N Am 1989: 3: 77-102.
29. LEVITZ SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 1991: 13: 1163-1169.
30. MILLER MF, MITCHELL TG. Killing of Cryptococcus neoformans strains by human neutrophils and monocytes. Infect Immun 1991: 59: 24-28.
31. SCHAFFNER A, DAVIS CE, SCHAFFNER T, MARKET M, DOUGLAS H, BRAUDE AI. In vitro susceptibility of fungi to killing by neutrophil granulocytes discriminates between primary pathogenicity and opportunism. J Clin Invest 1986: 78: 511-524.
32. CLANCY CJ, NGUYEN MH. Acute community-acquired pneumonia due to Aspergillus in presumably immunocompetent hosts: clues for recognition of a rare but fatal disease. Chest 1998: 114: 629-634.
33. SCHMALDIENST S, HORL WH. Bacterial infections during immunosuppression-immunosuppressive agents interfere not only with immune response, but also polymorphonuclear cell function. Nephrol Dial Transplant 1996: 11: 1243-1245.
34. GROGAN JB, SMITH GV. Neutrophil function in clinical kidney allograft recipients. Surgery 1975: 78: 316-321.
35. GOLSHAN N, BARKER CF, MCGREGOR RR. Granulocyte function in recipients of renal transplants from live related donors and from cadavers. J Infect Dis 1980: 142: 876-883.
36. HORL WH, WANNER C, RIEGEL W, SCHLOSSER W, WILMS H, SCHOLLMEYER P. Reduction of degranulation of polymorphonuclear leukocytes by immunosuppression in patients following cadaveric renal transplantation. Transplantation 1989: 47: 144-148.
37. MEULMAN J, KATZ P. The immunologic effects, kinetics, and use of glucocorticoids. Med Clin N Am 1985: 69: 805-816.
38. SCHAFFNER A. Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma interferon. J Clin Invest 1985: 76: 1755-1764.
39. DUONG M, OUELLET N, SIMARD M, BERGERON Y, OLIVIER M, BERGERON MG. Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice. J Infect Dis 1998: 178: 1472-1482.
40. GUSTAFSON TL, SCHAFFNER W, LAVERY GB, STRATTON DW, JOHNSON HK. Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect Dis 1983: 148: 230-238.
41. KOTULOVA D, STEFANOVIC J. Phagocytic capacity of human leukocytes preincubated with imuran and prednisone. J Hyg Epidemiol Microbiol Immunol 1983: 27: 253-257.
42. THORAT SP, THATTE UM, PAI N, DAHANUKAR SA. Inhibition of phagocytes by cyclosporin in vitro. Q J Med 1994: 87: 311-314.
43. KHARZAMI A, SVENSON M, NIELSEN H, BIRGENS HS. Effect of cyclosporin A on human neutrophil and monocyte function. Scan J Immunol 1985: 21: 585-591.
44. GOTO Y, KONO T, ISHI M, SATO EF. Suppressive effects of cyclosporin A and FK-506 on superoxide generation in human polymorphonuclear leukocytes primed by tumor necrosis factor alpha. J Invest Dermatol 2000: 115: 986-989.
45. FORREST MJ, JEWELL ME, KOO GC, SIGAL NH. FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. Biochem Pharmacol 1991: 42: 1221-1228.
46. VECCHIARELLI A, CENCI E, MARCONI P, ROSSI R, RICCARDI C, BISTONI F. Immunosuppressive effect of cyclosporin A on resistance to systemic infection with Candida albicans. J Med Microbiol 1989: 30: 183-192.
47. ROILIDES E, ROBINSON T, SEIN T, PIZZO PA, WALSH TJ. In vitro and ex vivo effects of cyclosporin A on phagocytic host defenses against Aspergillus fumigatus. Antimicrob Agents Chemother 1994: 38: 2883-2888.
48. EGGER G, BURDA A, HENGSTER P, KUNC M, MARGREITER R. Polymorphonuclear leukocyte functions as predictive markers for infections after transplantation. Transpl Int 2000: 3: 114-121.
49. YAMAMOTO Y, KLEIN TW, FRIEDMAN H, YAMAGUChI H. Granulocyte colony-stimulating factor facilitates the restoration of resistance to opportunistic fungi in leukopenic mice. J Med Vet Mycol 1992: 30: 293-300.
50. DALE DC, LILES WC, SUMMER WR, NELSON S. Granulocyte colony-stimulating factor (G-CSF): roles and relationships in infectious diseases. J Infect Dis 1995: 172: 1061-1075.
51. STEVENS D. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 1998: 26: 1266-1269.
52. ROILIDES E, UHLIG K, VENZON D, PIZZO PA, WALSH TJ. Enhancement of oxidative responses to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993: 61: 1185-1193.
53. ROILIDES E, ULRGI K, VANZON D, PIZZO PA, WALSH TJ. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993: 61: 4870-4877.
54. GAVIRIA JM, VAN BURIK JAH, DALE DC, ROOT RK, LILES WC. Comparison of interferon-γ, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. J Infect Dis 1999: 179: 1038-1041.
55. VECCHIARELLI A, MONARI C, BALBELLI F, et al. Beneficial effects of recombinant granulocyte colony-stimulating factor on the fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. J Infect Dis 1995: 171: 1448-1454.
56. BISHOP MR, TARANTOLO SR, GELLER RB, et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000: 96: 80-85.
57. HUMPHREYS JM, RUGMAN FP, DAVIES JM, MINNAUGH P, HART CA, EDWARDS SW. Effects of recombinant human granulocyte colony-stimulating factor on neutrophil function in vitro and in vivo following chemotherapy and autologous bone marrow transplantation. J Clin Lab Immunol 1991: 34: 55-61.
58. ADAMS DH, WANG LF, BURNETT D, STOCKLEY RA, NEUBERGER JM. Neutrophil activation an important cause of tissue damage during liver allograft rejection? Transplantation 1990: 50: 86-91.
59. SCHMALDIENST S, BEKESI G, DIECHER R, FRANZ M, HORL WH, POHANKA E. Recombinant human granulocyte colony-stimulating factor after kidney transplantation: a retrospective analysis to evaluate the benefit or risk of immunostimulation. Transplantation 2000: 69: 527-531.
60. SINGHAL S, POWLES R, TRELEAVEN J, HORTON C, MEHTA J. Long-term safety of GM-CSF (molgramostim) administration after allogeneic bone marrow transplantation for hematologic malignancies: five-year follow-up of a double-blind randomized placebo-controlled study. Leuk Lymphoma 1997: 24: 301-307.
61. BHORADE SM, VENCE C, GARRITY ER, et al. The Loyola Lung Transplant Team. Treatment of infections in lung transplant patients with Filgrastim (G-CSF) does not induce rejection. Transplantation 1999: 67: S39.
62. WINSTON DJ, FOSTER PF, SOMBERG KA, et al. Randomized, placebo-controlled, doubleblind, multicenter trial of efficacy and safety of granulocyte colony-stimulating factor in liver transplant recipients. Transplantation 1999: 68: 1298-1304.
63. TURGEON N, HOVINGH GK, FISHMAN JA, et al. Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients. Transpl Infect Dis 2000: 2: 15-21.